- Pacira Pharmaceuticals (NASDAQ:PCRX +12.9%) Q4 results: Revenues: $72.9M (+5.2%); EXPAREL Sales: $71.4M (+6.3%); Operating Loss: ($2.5M) (-212.5%); Net Loss: ($4M) (-60.0%); Loss Per Share: ($0.11) (-57.1%); Non-GAAP EPS: $0.09 (-55.0%).
-
2016 results: Revenues: $276.4M (+11.0%); Operating Loss: ($32M); Net Loss: ($37.9M); Loss Per Share: ($1.02); Non-GAAP EPS: $0.62 (-34.7%); Quick Assets: $172.6M (+8.6%); CF Ops: $1M (0.0%).
-
2017 Guidance: EXPAREL net product sales: $290M - 310M; Non-GAAP R&D Expense: $50M - 60M; Non-GAAP SG&A Expense: $145M - 155M.
- A Phase 4 clinical trial assessing EXPAREL (bupivacaine liposome injectable suspension) in patients undergoing total knee replacement surgery met its co-primary endpoints for postsurgical pain and opioid reduction.